United States · FDA National Drug Code directory
FLUZONE HIGH DOSE NORTHERN HEMISPHERE
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 63552-722_42c83754-08e7-5327-e063-6294a90a126e
- Product NDC
- 63552-722
- Form
- INJECTION, SUSPENSION
- Composition / generic term
- influenza a virus a/victoria/4897/2022 ivr-238 (h1n1) antigen (formaldehyde inactivated), influenza a virus a/croatia/10136/rv/2023 (h3n2) antigen (formaldehyde inactivated), and influenza b virus b/michigan/01/2021 antigen (formaldehyde inactivated)
- Labeler
- Patheon Manufacturing Services LLC
- Marketing category
- BLA
- Marketing start / end (source format)
- 20250901
- Source listing expiry
- 20261231
Source-listed ingredients
- INFLUENZA A VIRUS A/CROATIA/10136RV/2023 X-425A (H3N2) ANTIGEN (FORMALDEHYDE INACTIVATED) — 60 ug/.5mL
- INFLUENZA B VIRUS B/MICHIGAN/01/2021 ANTIGEN (FORMALDEHYDE INACTIVATED) — 60 ug/.5mL
- INFLUENZA A VIRUS A/VICTORIA/4897/2022 IVR-238 (H1N1) ANTIGEN (FORMALDEHYDE INACTIVATED) — 60 ug/.5mL
These values do not establish equivalence or a dose recommendation.
Packages
- 5 SYRINGE, GLASS in 1 PACKAGE (63552-722-10) / .5 mL in 1 SYRINGE, GLASS (63552-722-05) · 63552-722-10
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →